Natera marked a -4.0% change today, compared to -1.0% for the S&P 500. Is it a good value at today's price of $47.21? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.
-
Natera belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 24.45 and an average price to book (P/B) of 4.16
-
The company's P/B ratio is 9.03
-
Natera has a trailing 12 month Price to Earnings (P/E) ratio of -10.2 based on its trailing 12 month price to earnings (EPS) of $-4.64 per share
-
Its forward P/E ratio is -17.2, based on its forward earnings per share (EPS) of $-2.74
-
Over the last four years, Natera has averaged free cash flows of $-175503333.3, which on average grew -0.0%
-
NTRA's gross profit margins have averaged 42.2 % over the last four years and during this time they had a growth rate of 0.1 % and a coefficient of variability of 14.6 %.
-
Natera has moved 2.0% over the last year compared to 17.0% for the S&P 500 -- a difference of -15.0%
-
NTRA has an average analyst rating of buy and is -36.32% away from its mean target price of $74.14 per share